Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic acquires Biophan MRI safety technology:

This article was originally published in Clinica

Executive Summary

Medtronic has acquired magnetic resonance imaging (MRI) safety patents from Biophan Technologies in a deal worth $11m. The acquisition, expected to close within 60 days, will see Medtronic purchase patents covering technologies that can make devices such as pacemakers safe for use with MRI, which can disrupt pacemakers because of the effect of the magnetic fields generated. Medtronic's range of pacemakers includes the EnPulse, EnRhythm and AT500 pacing systems, and the Kappa and Sigma product lines. Established in 2000, Pittsford, New York-based Biophan holds around 61 issued US patents and over 100 pending applications at various stages of examination. It will continue to work on the development of technologies to enable visualisation of clotting and restenosis in stents under MRI, a procedure which is not possible with current stents. The company will also continue its collaboration with its business partner Myotech, which aims to produce the Myotech circulatory support system, a device for the treatment of acute heart failure (see Clinica No 1215, p 21).

You may also be interested in...

Celltrion Invests $450m Into Incheon Manufacturing Site

Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market

Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts